- Home
- KNOP vs ALLO Comparison
KNOP vs ALLO Comparison
Compare KNOP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- ALLO
- Stock Information
- Founded
- KNOP 2013
- ALLO 2017
- Country
- KNOP United Kingdom
- ALLO United States
- Employees
- KNOP 874
- ALLO N/A
- Industry
- KNOP Marine Transportation
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNOP Consumer Discretionary
- ALLO Health Care
- Exchange
- KNOP Nasdaq
- ALLO Nasdaq
- Market Cap
- KNOP 243.2M
- ALLO 277.8M
- IPO Year
- KNOP 2013
- ALLO 2018
- Fundamental
- Price
- KNOP $6.97
- ALLO $1.30
- Analyst Decision
- KNOP
- ALLO Strong Buy
- Analyst Count
- KNOP 0
- ALLO 9
- Target Price
- KNOP N/A
- ALLO $8.44
- AVG Volume (30 Days)
- KNOP 61.1K
- ALLO 3.2M
- Earning Date
- KNOP 09-02-2025
- ALLO 08-06-2025
- Dividend Yield
- KNOP 1.48%
- ALLO N/A
- EPS Growth
- KNOP N/A
- ALLO N/A
- EPS
- KNOP 0.19
- ALLO N/A
- Revenue
- KNOP $320,026,000.00
- ALLO N/A
- Revenue This Year
- KNOP $9.28
- ALLO N/A
- Revenue Next Year
- KNOP N/A
- ALLO $199.63
- P/E Ratio
- KNOP $36.54
- ALLO N/A
- Revenue Growth
- KNOP 8.76
- ALLO N/A
- 52 Week Low
- KNOP $5.28
- ALLO $0.86
- 52 Week High
- KNOP $8.15
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- KNOP 60.20
- ALLO 46.23
- Support Level
- KNOP $6.29
- ALLO $1.13
- Resistance Level
- KNOP $7.21
- ALLO $1.26
- Average True Range (ATR)
- KNOP 0.24
- ALLO 0.08
- MACD
- KNOP 0.05
- ALLO -0.00
- Stochastic Oscillator
- KNOP 77.14
- ALLO 43.18
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.